| scholarly article | Q13442814 |
| P356 | DOI | 10.1089/HUM.2007.0171 |
| P8608 | Fatcat ID | release_tkyqv2izjba3vfikugv2jwyfou |
| P932 | PMC publication ID | 2656366 |
| P698 | PubMed publication ID | 18444786 |
| P5875 | ResearchGate publication ID | 5407228 |
| P50 | author | Steven Rosenberg | Q2347448 |
| Bianca Heemskerk | Q114017568 | ||
| P2093 | author name string | Paul F Robbins | |
| Laura A Johnson | |||
| Ke Liu | |||
| Andrew Kaiser | |||
| Richard A Morgan | |||
| Zhili Zheng | |||
| Mark E Dudley | |||
| Kant Matsuda | |||
| Thomas E Shelton | |||
| Stephanie Downey | |||
| P2860 | cites work | Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells | Q24540135 |
| CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. | Q24540429 | ||
| Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma | Q24548019 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression | Q33230754 | ||
| A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma | Q33342339 | ||
| Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells | Q33831940 | ||
| Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. | Q34314036 | ||
| Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells | Q34415738 | ||
| Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine | Q34657676 | ||
| IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients | Q34657691 | ||
| Telomeres in T and B cells | Q34810292 | ||
| Retrovirus silencing and vector design: relevance to normal and cancer stem cells? | Q36230366 | ||
| Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody | Q36294795 | ||
| Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy | Q36328394 | ||
| Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. | Q36371632 | ||
| The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design | Q36547207 | ||
| Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients | Q36551911 | ||
| Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity | Q36726945 | ||
| Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy | Q36908563 | ||
| Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent | Q36908573 | ||
| Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. | Q37418499 | ||
| Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence | Q40662338 | ||
| CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes | Q40669542 | ||
| In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. | Q40815147 | ||
| The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. | Q40897726 | ||
| IL-2 regulates perforin and granzyme gene expression in CD8+ T cells independently of its effects on survival and proliferation | Q46844014 | ||
| L-selectin-negative CCR7- effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. | Q51974964 | ||
| Transfer of the human telomerase reverse transcriptase (TERT) gene into T lymphocytes results in extension of replicative potential. | Q52018513 | ||
| Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients | Q69548004 | ||
| Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells | Q81357564 | ||
| P433 | issue | 5 | |
| P921 | main subject | lymphocyte | Q715347 |
| patient | Q181600 | ||
| interleukins | Q194908 | ||
| P304 | page(s) | 496-510 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | Human Gene Therapy | Q15757580 |
| P1476 | title | Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. | |
| P478 | volume | 19 |
| Q37201423 | "Model t" cells: a time-tested vehicle for gene therapy |
| Q41203830 | A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes |
| Q35886450 | Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination |
| Q90398709 | Adoptive Cell Therapy-Harnessing Antigen-Specific T Cells to Target Solid Tumours |
| Q34977470 | Adoptive T cell therapy of cancer |
| Q37389018 | Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. |
| Q27027803 | Advances in the treatment of metastatic melanoma: adoptive T-cell therapy |
| Q40056727 | An adaptive immune response driven by mature, antigen-experienced T and B cells within the microenvironment of oral squamous cell carcinoma |
| Q37952804 | Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy? |
| Q36016696 | Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice |
| Q38199347 | CD28z CARs and armored CARs |
| Q84669662 | Cellular Immunotherapy of Cancer |
| Q38011650 | Challenges in T cell receptor gene therapy. |
| Q37469199 | Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity |
| Q38987239 | Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them |
| Q55220988 | Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model. |
| Q88010589 | Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma |
| Q39200527 | Development of CAR T cells designed to improve antitumor efficacy and safety |
| Q92221483 | Development of an Interleukin-12 Fusion Protein That Is Activated by Cleavage with Matrix Metalloproteinase 9 |
| Q54667188 | Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model. |
| Q34020065 | Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma |
| Q34667739 | Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice |
| Q37854259 | Ex vivo gene transfer for improved adoptive immunotherapy of cancer |
| Q33905311 | Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy |
| Q64230023 | Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines |
| Q39778480 | Genetic immunotherapy of lung cancer using conditionally replicating adenovirus and adenovirus-interferon-beta |
| Q34644876 | Genetic modification of T cells |
| Q37697337 | Genetic redirection of T cells for cancer therapy. |
| Q33839836 | IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice |
| Q37738706 | Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). |
| Q34181954 | Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma |
| Q36453216 | Immunotherapy for melanoma: current status and perspectives |
| Q36470354 | Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells |
| Q28068378 | Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination |
| Q37183063 | Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer |
| Q58779761 | Interleukin-15 suppresses gastric cancer liver metastases by enhancing natural killer cell activity in a murine model |
| Q38849182 | Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells. |
| Q38646138 | Novel Treatments in Development for Melanoma. |
| Q37486788 | Novel therapeutics for the treatment of metastatic melanoma |
| Q50198645 | Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques |
| Q37653325 | Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells |
| Q36334073 | PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines |
| Q34557896 | PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells |
| Q26741260 | Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors |
| Q50035774 | Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors |
| Q34122292 | Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor |
| Q35749986 | Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? |
| Q27680213 | Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity |
| Q28081611 | T-cell receptor gene therapy--ready to go viral? |
| Q38775177 | The future of cancer treatment: immunomodulation, CARs and combination immunotherapy |
| Q50515567 | The position of the AUG start codon in MFG-based γ-retroviral vectors has a dramatic effect on translation-dependent protein expression. |
| Q42205916 | Towards neuroimmunotherapy for cancer: the neurotransmitters glutamate, dopamine and GnRH-II augment substantially the ability of T cells of few head and neck cancer patients to perform spontaneous migration, chemotactic migration and migration towa |
| Q36333963 | Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses |
| Q42702234 | Trial Watch: Adoptive cell transfer for anticancer immunotherapy |
| Q36057432 | Trial Watch: Adoptive cell transfer immunotherapy |
| Q33734281 | Vaccines against human carcinomas: strategies to improve antitumor immune responses |
Search more.